Vitols family invests in established cancer virotherapy excellence center
06.06.2016

"VVMV" holding owned by "Vītolu Fonds" founders Vilis and Marta purchased 5% of Global Virotherapy Cancer Clinic (GVCC) shares, thus becoming one of the clinics cancer virotherapy shareholders. "This is the first "VVMV" investment related to the medical industry. We appreciate a lot the opportunity to contribute to the clinic, which innovatively works in the virotherapy field, continuing scientists Aina Muceniece life's work that is so important for cancer virotherapy development. The company's shareholders and management activities confirm the continuity of this great work. It is our shared opportunity to introduce international society with Latvian scientific progress and to help people" says Vilis Vitols.